{"id":2559,"date":"2018-02-22T17:28:25","date_gmt":"2018-02-22T11:58:25","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2559"},"modified":"2021-07-24T12:56:56","modified_gmt":"2021-07-24T07:26:56","slug":"business-cocktail-latest-pharma-deals","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals","title":{"rendered":"The Business Cocktail : Latest Pharma deals"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Ionis pharmaceuticals recently licensed-out its antisense drug to AstraZeneca in deal total worth up to USD 330 million<\/strong><\/p>\n<p style=\"text-align: justify;\">Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee. AstraZeneca will now be taking care of the development and commercialization of IONIS-AZ5-2.5Rx, designed to treat the kidney disease. Ionis will receive up to USD 300 million more in tiered royalties as well as development and regulatory milestones making it a USD 330 million deal in total.<\/p>\n<p style=\"text-align: justify;\"><strong>Roche has signed a deal worth USD 1.9 billion to buy Flatiron<\/strong><\/p>\n<p style=\"text-align: justify;\">Pharma industry giant Roche has recently signed a deal worth USD 1.9 billion deal to acquire oncology data firm Flatiron Health. The deal gives Roche complete ownership of the cancer software and a repository of real-world cancer evidence making the venture backed\u00a0by Google a rising star. Real-world evidence is the key driver of this deal according to the company.<\/p>\n<p style=\"text-align: justify;\"><strong>Merck along with three partners has started ExploreBio in Israel, an EUR 20 million pre-seed investment initiative<\/strong><\/p>\n<p style=\"text-align: justify;\">Merck, a US-based major pharma company has recently announced ExploreBio. A pre-seed-investment vehicle initiated by four investment funds targeted at nurturing early-stage companies in the biotechnology domain in Israel. The Strategic corporate venture capital arm of Merck has partnered with three partners namely Pontifax, Arkin Holdings, and WuXi AppTec to create the EUR 20 million pre-seed investment vehicle.<\/p>\n<p style=\"text-align: justify;\"><strong>Bristol-Myers Squibb and Nektar Therapeutics has collaborated on the global development &amp; commercialization of Nectar\u2019s NKTR-214 drug<\/strong><\/p>\n<p style=\"text-align: justify;\">Bristol-Myers Squibb Company and Nektar Therapeutics has recently announced that they have collaborated on the global strategic development and commercialization for Nektar&#8217;s NKTR-214 (lead immuno-oncology program). Now the companies will work together to develop and commercialize Nectar\u2019s NKTR-214 in combination with Bristol-Myers Squibb&#8217;s Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ionis pharmaceuticals recently licensed-out its antisense drug to AstraZeneca in deal total worth up to USD 330 million Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee. AstraZeneca will now be taking care of the development and commercialization of IONIS-AZ5-2.5Rx, designed to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1442,96,130,776,1118,204,1439,1437,1438,1440,1436,395,1444,1416,639,1196,1441,524,1443],"industry":[17225],"therapeutic_areas":[17230,17228],"class_list":["post-2559","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-arkin-holdings","tag-astrazeneca","tag-bristol-myers-squibb","tag-business-cocktail","tag-business-research","tag-delveinsight","tag-flatiron","tag-ionis-pharmaceuticals","tag-ionis-az5-2-5rx","tag-israel","tag-latest-pharma-research","tag-merck","tag-nektar-therapeutics","tag-nktr-214","tag-pharma-news","tag-pharma-research","tag-pontifax","tag-roche","tag-wuxi-apptec","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Business cocktail- latest pharmaceutical industry News<\/title>\n<meta name=\"description\" content=\"Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Business cocktail- latest pharmaceutical industry News\" \/>\n<meta property=\"og:description\" content=\"Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-22T11:58:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2450\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Business cocktail- latest pharmaceutical industry News","description":"Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals","og_locale":"en_US","og_type":"article","og_title":"The Business cocktail- latest pharmaceutical industry News","og_description":"Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee.","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-02-22T11:58:25+00:00","article_modified_time":"2021-07-24T07:26:56+00:00","og_image":[{"width":2450,"height":1080,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals","name":"The Business cocktail- latest pharmaceutical industry News","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","datePublished":"2018-02-22T11:58:25+00:00","dateModified":"2021-07-24T07:26:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-deals#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","width":2450,"height":1080,"caption":"News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop-300x132.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Arkin Holdings<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Cocktail<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Flatiron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ionis pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IONIS-AZ5-2.5Rx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Israel<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">latest pharma research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nektar Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NKTR-214<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pontifax<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">WuXi AppTec<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Arkin Holdings<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/span>","<span class=\"advgb-post-tax-term\">Business Cocktail<\/span>","<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Flatiron<\/span>","<span class=\"advgb-post-tax-term\">Ionis pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">IONIS-AZ5-2.5Rx<\/span>","<span class=\"advgb-post-tax-term\">Israel<\/span>","<span class=\"advgb-post-tax-term\">latest pharma research<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Nektar Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">NKTR-214<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma research<\/span>","<span class=\"advgb-post-tax-term\">Pontifax<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">WuXi AppTec<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 22, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 22, 2018 5:28 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2559"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2559\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2434"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2559"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2559"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}